Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 6:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 61 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Amiodarone Hydrochloride Clear all
Completed Phase 3 Interventional Results available

Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia

NCT01401647
View directory record Official record
Conditions
Cardiac Arrest
Interventions
amiodarone, Lidocaine, Normal saline
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
3,024 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
7
States / cities
Birmingham, Alabama • San Diego, California • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Sep 20, 2026, 6:52 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence

NCT04704050
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Fibrillation Recurrent
Interventions
dronedarone 400 mg Oral Tablet, Placebo
Drug
Lead sponsor
Tulane University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Colorado Springs, Colorado • Atlanta, Georgia • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 20, 2026, 6:52 AM EDT
Completed Not applicable Interventional Results available

Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial

NCT00578617
View directory record Official record
Conditions
Atrial Fibrillation, Arrhythmia
Interventions
Rate Control, Ablation Therapy, Rhythm control
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
10
States / cities
Birminham, Alabama • Los Angeles, California • Maywood, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 20, 2026, 6:52 AM EDT
Terminated Phase 4 Interventional

Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control

NCT02025465
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Metoprolol, Diltiazem
Drug
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 20, 2026, 6:52 AM EDT
Completed No phase listed Observational

A Pharmaco-surgical Approach to Reduce Postoperative Atrial Fibrillation After Cardiac Surgery

NCT05780320
View directory record Official record
Conditions
Atrial Fibrillation New Onset
Interventions
Prophylactic amiodarone and posterior pericardiotomy
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Sep 20, 2026, 6:52 AM EDT
Not listed Phase 4 Interventional

Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy(PAPS)

NCT03228823
View directory record Official record
Conditions
Ventricular Premature Beats, Contractions, or Systoles, Cardiomyopathies
Interventions
Radiofrequency ablation, Amiodarone (Antiarrhythmic drug)
Procedure · Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Sep 20, 2026, 6:52 AM EDT
Completed Phase 4 Interventional

Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation

NCT05130268
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Dronedarone
Drug
Lead sponsor
American Heart Association
Other
Eligibility
21 Years and older
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
103
States / cities
Fairhope, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 20, 2026, 6:52 AM EDT
Completed Phase 3 Interventional Results available

Efficacy & Safety of Dronedarone Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation

NCT00489736
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
dronedarone (SR33589), amiodarone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 17, 2010 · Synced Sep 20, 2026, 6:52 AM EDT
Terminated Phase 4 Interventional Results available

Use of Amiodarone in Atrial Fibrillation Associated With Severe Sepsis or Septic Shock

NCT02668432
View directory record Official record
Conditions
New Onset Atrial Fibrillation, Severe Sepsis, Septic Shock
Interventions
Amiodarone
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Sep 20, 2026, 6:52 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation

NCT01522651
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Ranolazine, Dronedarone, Ranolazine placebo, Dronedarone placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
15
States / cities
Beverly Hills, California • Newport Beach, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Sep 20, 2026, 6:52 AM EDT
Completed Phase 4 Interventional

Prevention of Post-OP AFib Using Combination of CardiaMend and Amiodarone

NCT05681182
View directory record Official record
Conditions
Post Operative Atrial Fibrillation
Interventions
CardiaMend with the Addition of Amiodarone
Combination Product
Lead sponsor
WakeMed Health and Hospitals
Other
Eligibility
20 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Sep 20, 2026, 6:52 AM EDT
Completed Phase 4 Interventional

Ablation vs Amiodarone for Treatment of AFib in Patients With CHF and an ICD

NCT00729911
View directory record Official record
Conditions
Heart Failure
Interventions
Atrial Fibrillation ablation, Amiodarone
Procedure · Drug
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Sep 20, 2026, 6:52 AM EDT
Suspended Phase 3 Interventional

High Intensity Focused Ultrasound (HIFU) Ablation System Study

NCT00392106
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
propafenone, flecainide, dofetilide, sotolol, Pulmonary vein ablation, Amiodarone
Drug · Device
Lead sponsor
ProRhythm, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
20
States / cities
Fullerton, California • Los Angeles, California • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2008 · Synced Sep 20, 2026, 6:52 AM EDT
Completed Phase 4 Interventional Results available

Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation

NCT05391893
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Oral, Intravenous drug
Drug
Lead sponsor
Corewell Health South
Other
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Saint Joseph, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 20, 2026, 6:52 AM EDT
Recruiting Phase 1Phase 2 Interventional

Amiodarone-Infused CardiaMend Patches for the Prevention of New-Onset POAF in Cardiac Surgery Subjects

NCT06730828
View directory record Official record
Conditions
Atrial Fibrillation, Postoperative
Interventions
The intervention includes Amiodarone-Infused CardiaMend patches (70mg, 150mg and 300mg)
Combination Product
Lead sponsor
Helios Cardio Inc.
Industry
Eligibility
20 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Sep 20, 2026, 6:52 AM EDT
Terminated Not applicable Interventional Results available

Combined Amiodarone and Electrical Cardioversion for Postoperative Atrial Fibrillation After Cardiac Surgery

NCT01558128
View directory record Official record
Conditions
Cardiac Disease
Interventions
Amiodarone, Cardioversion
Drug · Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Sep 20, 2026, 6:52 AM EDT
Terminated Phase 4 Interventional Results available

Effects of Dronedarone on Atrial Fibrillation Burden in Subjects With Permanent Pacemakers

NCT01135017
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Dronedarone, Placebo (for Dronedarone)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
92
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Sep 20, 2026, 6:52 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Prevention of Postop Atrial Fibrillation Through Intraoperative Inducibility of Atrial Fibrillation and Amiodarone Treatment

NCT03868150
View directory record Official record
Conditions
Postoperative Atrial Fibrillation
Interventions
Amiodarone Injection, Intraoperative Rapid Atrial Pacing
Drug · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2050
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 20, 2026, 6:52 AM EDT
Active, not recruiting Phase 3 Interventional

Amiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery

NCT02750319
View directory record Official record
Conditions
Thoracic Surgery, Atrial Fibrillation in High Risk Patients
Interventions
Amiodarone, N-Acetylcysteine, Placebo
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
9
States / cities
St Louis, Missouri • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 20, 2026, 6:52 AM EDT
Completed Phase 3 Interventional

American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm

NCT00259376
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Dronedarone (SR33589), placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 14, 2010 · Synced Sep 20, 2026, 6:52 AM EDT
Completed Phase 3 Interventional Results available

Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation

NCT02132767
View directory record Official record
Conditions
Postoperative Atrial Fibrillation
Interventions
Amiodarone, DC-cardioversion, Rate Control
Drug · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Sep 20, 2026, 6:52 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404
View directory record Official record
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 20, 2026, 6:52 AM EDT
Terminated Not applicable Interventional Results available

Radiofrequency Ablation for Amiodarone-induced Thyrotoxicosis

NCT03720210
View directory record Official record
Conditions
Amiodarone-Induced Thyrotoxicosis
Interventions
RFA
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 20, 2026, 6:52 AM EDT
Active, not recruiting Not applicable Interventional

Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation

NCT06096337
View directory record Official record
Conditions
Persistent Atrial Fibrillation
Interventions
FARAPULSE™ Pulsed Field Ablation (PFA) System, Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 20, 2026, 6:52 AM EDT